oteseconazole
Sign in to saveOteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC).
In the Vinony graph
Within Vinony's link graph, oteseconazole is referenced by 93 other articles, and connects out to phase of clinical research, digital object identifier and chemical formula.
It sits within the topics Biaryls, Disubstituted pyridines and ECHA InfoCard ID from Wikidata.
Its subject is documented across 7 Wikipedia language editions.
Wikidata facts
- Mass
- 527.119
Show 4 more facts
- canonical SMILES
- C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
- chemical formula
- C₂₃H₁₆F₇N₅O₂
- isomeric SMILES
- C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
- Commons category
- Oteseconazole
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Society and culture
- Names
- Mechanism of action
- Adverse effect and interaction
- References
- External links
Oteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC).
Marketed under the brand name Vivjoa, this medication was developed by Mycovia Pharmaceuticals and received approval for medicinal use from United States Food and Drug Administration (US FDA) in April 2022.
Excerpted from Wikipedia’s “oteseconazole” article, available under the CC BY-SA 4.0 licence.